about
Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor.Hepatic manifestations of non-steroidal inflammatory bowel disease therapyIsoniazid metabolism and hepatotoxicityEvaluation of isoniazid-associated hepatitis by immunological testsIsoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosisLate effects following isoniazid therapyIsoniazid-related fatal hepatitis.Mechanism of isoniazid‐induced hepatotoxicity: then and nowIsoniazid and action tremor in multiple sclerosisAntitubercular therapy in patients with cirrhosis: challenges and optionsEvaluation of prognostic markers in severe drug-induced liver disease.Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicityPiroxicam induced submassive necrosis of the liver.Clinicopathological correlates in HIV seropositive tuberculosis cases presenting with jaundice after initiating antiretroviral therapy with a structured review of the literaturePortal fibrosis in the livers of alcoholic patients.Hepatic reactions to drugs.Drug hepatotoxicity.Hepatotoxicity to sodium valproate: a review.Adverse events associated with treatment of latent tuberculosis in the general population.The role of biotransformation in chemical-induced liver injury.Isoniazid liver injury during chemoprophylaxis in childrenN-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark.Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study.Pathologic aspects of cirrhosis. A review.Direct oxidation and covalent binding of isoniazid to rodent liver and human hepatic microsomes: humans are more like mice than rats.Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications.Antituberculosis treatment-induced hepatotoxicity: role of predictive factors.Eosinophils mediate the pathogenesis of halothane-induced liver injury in miceCYP2E1-dependent elevation of serum cholesterol, triglycerides, and hepatic bile acids by isoniazid.Risk Factors of Hepatotoxicity During Anti-tuberculosis Treatment.Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failureInterplay of factors leading to adverse drug reactions in the liver, a personal viewpoint.A study of the effect of Nigella sativa (Black seeds) in isoniazid (INH)-induced hepatotoxicity in rabbitsIsoniazid hepatotoxicity: progress in understanding the immunologic component.Drug-induced liver injury: is it somehow foreseeable?Impairment of Mitochondrial Biogenesis and Dynamics Involved in Isoniazid-Induced Apoptosis of HepG2 Cells Was Alleviated by p38 MAPK Pathway.
P2860
Q25255438-E9E6FD33-BA18-4EC0-9B23-C22B4A67D1ECQ26773684-F13B7437-9234-412C-A3D7-CCC09C8924CFQ28076859-30100068-1061-4A46-A27E-FE991A886DCCQ28332812-708219CB-F45F-439A-BB9A-9E95868704AEQ28362291-91E9A193-4C24-4AB5-B753-E94AB9F3195CQ28367172-DF0C6030-65EE-4B4E-B0D0-8366582CF757Q28379062-9DDD1F9D-6516-4068-B0F8-62EDD4CE891DQ29248263-A8E79B1A-860E-407F-8C61-FFD20AFFA762Q33620898-F1C1AB6C-F7F6-4A47-9796-2FB64192730FQ33626827-FA215CA2-F9B2-48BE-BC39-2FB00C49408BQ33787967-43671339-CBC3-4D65-A2EE-837AF6111B61Q34200596-95B905ED-B767-4FC2-8FC6-D5058B17D8B9Q34396654-7FFC1C32-9685-45C2-97FA-FEE2B7B40A85Q34444338-BD9DE919-CD67-42C8-BF94-43C1F52C17E2Q34475048-C734E196-22B3-44A4-912F-705108CD2E3DQ34475653-4A874F37-34BF-463A-9F94-F31CBE70EBC8Q34512476-6F03DFBF-C128-4C73-95EB-DFD1813845B6Q34525582-6C2285EF-4383-4791-B1B1-AC193D5ACB4EQ34589993-0AE211C9-2FF5-4EDF-B3D3-BF0F5C119B8EQ34663568-2736D126-44C7-4719-9D27-B18943C1330DQ34986936-658A269C-3E63-49C6-95F8-C92209499802Q35133059-DF25BDB7-C07A-4BFB-9F07-85F663B6F201Q35656015-A1F7495A-AEDB-42A1-B795-075AC9A50919Q36076957-740E755E-0287-4D16-9D80-7BECC4766ACEQ36408248-E264F858-8FA9-4360-ABB4-14250EB0076CQ36479455-3EA53FBD-A303-41B4-81F0-3ED08B5D1D77Q36680092-58751AAF-BE9E-4542-AB56-29760FC668CAQ36724588-CF14FB5D-30AA-4815-A083-3DB21BDA0C64Q36867088-3B594A31-67FD-4E2D-B4A1-D09E5946D3E1Q37043444-0A470582-43C7-480B-A046-7697DB2A9F33Q37082852-C53A8BEB-7C88-4C6F-BCC9-6A10BA9AD923Q41212100-B6095BBB-0324-4913-9373-DACDE332AB48Q42413071-1C92A8C1-6EED-4DA9-BE60-D88E672373A2Q42775512-BF20FD1F-63D7-46DC-8696-8912745BF9F7Q43109156-A4739FDF-F778-4104-B7BF-719F0B9F7462Q47093593-C2B64B6A-ED39-4ECA-A9BD-B60F1235F891
P2860
description
1975 nî lūn-bûn
@nan
1975 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1975 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1975年の論文
@ja
1975年論文
@yue
1975年論文
@zh-hant
1975年論文
@zh-hk
1975年論文
@zh-mo
1975年論文
@zh-tw
1975年论文
@wuu
name
Isoniazid-associated hepatitis in 114 patients
@ast
Isoniazid-associated hepatitis in 114 patients
@en
Isoniazid-associated hepatitis in 114 patients
@nl
type
label
Isoniazid-associated hepatitis in 114 patients
@ast
Isoniazid-associated hepatitis in 114 patients
@en
Isoniazid-associated hepatitis in 114 patients
@nl
prefLabel
Isoniazid-associated hepatitis in 114 patients
@ast
Isoniazid-associated hepatitis in 114 patients
@en
Isoniazid-associated hepatitis in 114 patients
@nl
P2093
P3181
P1433
P1476
Isoniazid-associated hepatitis in 114 patients
@en
P2093
H J Zimmerman
J R Mitchell
P304
P3181
P407
P577
1975-08-01T00:00:00Z